Clinical Trial

First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)

Study acronym: Artemis
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 23, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
A phase II, investigator-initiated, non-randomized, open-label, single-arm, multicenter study to evaluate the efficacy and safety of Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab combination for previously untreated advanced or recurrent thymic carcinomas
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-04-16.
Status change: Not Yet Recruiting → Recruiting 2023-10-18
Trial Details
NCT Number NCT05832827
Lead Sponsor National Cancer Center, Japan
Collaborators: Merck Sharp & Dohme LLC
Conditions Untreated Advanced or Recurrent Thymic Carcinomas
Enrollment 35 participants
Start Date 2023-09-04
Primary Completion 2025-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2023-10-23